Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-12-05Clinical Trial Update: Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM) [Phase 2]
Phase 2 clinical trial update on pomalidomide for relapsed and refractory multiple myeloma (RRMM).
-
CLINICAL_TRIALS trial_result · 2024-12-04Clinical Trial Update: Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma [Phase 3]
Phase 3 clinical trial update on managing pain and chemotherapy-related symptoms in people with multiple myeloma or lymphoma, with results p…
-
CLINICAL_TRIALS trial_result · 2024-12-03Clinical Trial Update: Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy [Phase 2]
This clinical trial update reports Phase 2 results for Descartes-11 used as consolidation therapy in high-risk multiple myeloma patients wit…
-
CLINICAL_TRIALS trial_result · 2024-12-03Clinical Trial Update: Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies [Phase 2]
This Phase 2 trial studied the combination of lenalidomide and ipilimumab after stem cell transplantation in patients with hematologic or ly…
-
CLINICAL_TRIALS research · 2024-12-03Clinical Trial Update: Examination of Vertebroplasty in Addition to Regular Treatment of Patients With Multiple Myeloma. [NA]
This document reports on an ongoing clinical trial evaluating vertebroplasty in addition to standard treatment for patients with multiple my…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-12-03Clinical Trial Update: PRospective Multiple Myeloma Impact Study [NA]
A prospective study investigating outcomes in patients with multiple myeloma, sponsored by SkylineDx, currently active but not recruiting.
-
FDA approval · 2024-12-02FDA Approved: TALVEY — Supplemental Application (Janssen Biotech, Inc.)
FDA approved Janssen Biotech's supplemental application for TALVEY (talquetamab), updating its labeling to reflect the approved changes. TAL…
-
FDA approval · 2024-12-02FDA Approved: TECVAYLI — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for TECVAYLI (teclistamab-cqyv) by Janssen Biotech, Inc.
-
CLINICAL_TRIALS research · 2024-11-29Clinical Trial Update: Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma
A clinical trial comparing the combination of bortezomib, bendamustine, and melphalan versus melphalan alone for multiple myeloma is current…
-
CLINICAL_TRIALS research · 2024-11-29Clinical Trial Update: A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) [Phase 1, Phase 2]
A Phase 1/2 trial evaluating CC-92480 in combination with standard treatments for relapsed/refractory and newly diagnosed multiple myeloma t…
-
CLINICAL_TRIALS research · 2024-11-27Clinical Trial Update: A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant [Phase 3]
A Phase 3 trial sponsored by Sanofi is evaluating isatuximab with bortezomib, lenalidomide and dexamethasone in adults with newly diagnosed …
-
CLINICAL_TRIALS research · 2024-11-26Clinical Trial Update: A Multicenter Cross-sectional Study on Mental Health of Patients With Multiple Myeloma
A multicenter cross-sectional study (completed) examining psychological distress, insomnia, and somatic symptoms in patients with multiple m…
-
CLINICAL_TRIALS trial_result · 2024-11-26Clinical Trial Update: Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma [Phase 1]
A Phase I study evaluating CBG002 CAR-T cell therapy for relapsed or refractory multiple myeloma; the trial is not yet recruiting.
-
CLINICAL_TRIALS research · 2024-11-25Clinical Trial Update: Risk Stratification and MRD-driven Maintenance for MM After ASCT [NA]
A recruiting clinical trial from Peking University People's Hospital is investigating risk stratification and MRD-driven maintenance therapy…
-
CLINICAL_TRIALS withdrawal · 2024-11-25Clinical Trial Update: Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
A Travera Inc clinical trial (NCT04985357) evaluating mass response as a biomarker for tumor sensitivity to drugs has been withdrawn; no res…
-
FDA approval · 2024-11-22FDA Approved: TECVAYLI — Supplemental Application (Janssen Biotech, Inc.)
FDA has approved a supplemental application for TECVAYLI (teclistamab-cqyv) by Janssen Biotech, Inc., potentially updating the labeling or i…
-
CLINICAL_TRIALS research · 2024-11-22Clinical Trial Update: Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan [Phase 3]
Phase 3 trial comparing two olanzapine dosing regimens (2.5 mg vs 5 mg) for nausea/vomiting prophylaxis before high-dose melphalan in autolo…
-
CLINICAL_TRIALS trial_result · 2024-11-20Clinical Trial Update: A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China [Phase 1]
Phase 1 clinical trial update evaluating Maplirpacept in advanced non-Hodgkin lymphoma or multiple myeloma in China has completed.
-
CLINICAL_TRIALS withdrawal · 2024-11-19Clinical Trial Update: Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma [Phase 1, Phase 2]
A Phase 1/2 trial of mezigdomide plus ixazomib and dexamethasone for relapsed and refractory multiple myeloma has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2024-11-19Clinical Trial Update: Mobile Health Device Study for Myeloma Patients
A completed clinical trial evaluating a mobile health device for patients with multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2024-11-18Clinical Trial Update: Anakinra: Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT - A Randomized Controlled Trial [Phase 2]
Phase 2 randomized trial evaluating the efficacy of anakinra for managing fever during neutropenia and mucositis in autologous stem cell tra…
-
CLINICAL_TRIALS trial_result · 2024-11-18Clinical Trial Update: Anakinra: Safety and Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT [Phase 2]
Phase 2 trial evaluating the safety and efficacy of anakinra for managing fever during neutropenia and mucositis in autologous stem cell tra…
-
CLINICAL_TRIALS trial_result · 2024-11-13Clinical Trial Update: Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd) [Phase 1, Phase 2]
A Phase 1/2 clinical trial update on weekly combination therapy with carfilzomib, cyclophosphamide, and dexamethasone (wCCyd) in newly diagn…
-
CLINICAL_TRIALS trial_result · 2024-11-12Clinical Trial Update: Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL [Phase 1]
Phase 1 trial evaluating haploidentical stem cell transplantation with prophylactic natural killer donor lymphocyte infusion in lymphoma, mu…
-
CLINICAL_TRIALS other · 2024-11-12Clinical Trial Update: 64Cu-LLP2A for Imaging Multiple Myeloma [EARLY_Phase 1]
An early-phase 1 imaging trial of the radiotracer 64Cu-LLP2A for multiple myeloma was terminated.